Senzime Reaffirms Its Target of Reaching Positive Cash Flow Within Q4 2026
Preliminary double-digit sales growth accompanies challenges in fully achieving the year's revenue growth targets.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Senzime (SNZZF) reaffirmed its target of reaching positive cash flow within the fourth quarter of 2026 despite revenue growth challenges.
The company said it faces challenges in fully achieving its revenue growth targets for the year. Preliminary Q3 2026 figures indicate double-digit sales growth and further improved gross margins, alongside continued cost control and optimized working capital. These are preliminary indicators, not the full quarterly results.
Senzime identifies these operating and working-capital developments as drivers toward its positive cash flow target. The target remains a future goal rather than an achieved result. The full Q3 2026 report is scheduled for release on October 29, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Senzime reaffirmed its target of positive cash flow within Q4 2026.
- Moderate pointPreliminary Q3 2026 sales indicate double-digit growth.
- Moderate pointPreliminary Q3 2026 gross margins indicate further improvement.
- Minor pointPreliminary Q3 2026 figures indicate continued cost control.
- Minor pointPreliminary Q3 2026 figures indicate optimized working capital.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.2026 revenue growth targets face challenges to full achievement, Senzime said.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UPPSALA, SE / ACCESS Newswire / October 5, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - "We reaffirm our target of reaching positive cash flow within the fourth quarter of 2026, despite seeing challenges in fully achieving the ambitious revenue growth targets we set for the year. Preliminary Q3 figures now indicate double-digit sales growth, further improved gross margins, continued cost control and optimized working capital, all of which are important drivers toward achieving our positive cash flow target," comments Philip Siberg, CEO of Senzime.
The full Q3 2026 report will be released as scheduled on October 29, 2026.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com
About Senzime
Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.
Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.
This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-10-05 16:00 CEST.
Attachments
Senzime reaffirms its target of reaching positive cash flow within Q4 2026
SOURCE: Senzime
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Senzime target positive cash flow?
Senzime reaffirmed its target of reaching positive cash flow within the fourth quarter of 2026. This remains a target, not a completed milestone.